Hematologist
CION Cancer Clinics
CAR-T or a stem cell transplant: which comes first? | CION Cancer Clinics
It depends on your blood cancer and how it behaved. For large B-cell lymphoma that does not respond or returns within about a year, CAR-T is now often used before a transplant. For later relapses, myeloma and many leukaemias, a transplant usually still comes first. This page explains what decides the order, who each option does not suit, and what to ask your haematologist. At CION Cancer Clinics, our haematology team assesses whether a transplant or CAR-T fits your situation and coordinates care with qualified centres.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Which usually comes first, CAR-T or a transplant?
- What are the three options, in plain words?
- How do CAR-T and a transplant differ for the family?
- What does the team look at before choosing?
- Who is each option not right for?
- What do the words in the letters mean?
- What do families get wrong about this choice?
- Common questions about CAR-T and transplant
The short answer
Which usually comes first, CAR-T or a transplant?
It depends on the blood cancer, how it responded to the first treatment, and how soon it came back. For many people a stem cell transplant is still the standard next step, and CAR-T is kept for when that route has failed or is unlikely to work.
Where the order has changed
In large B-cell lymphoma, the picture shifted in the last few years. When the lymphoma does not respond to first treatment, or returns within about a year of finishing it, large trials found CAR-T given as the second treatment did better than the older route of more chemotherapy followed by an autologous transplant (a transplant using your own stem cells). When the lymphoma returns later than that, the transplant route is still widely used.
Where transplant still leads
In myeloma, a transplant using your own cells is usually part of the first plan for people fit enough, and CAR-T is used after later relapses. In acute lymphoblastic leukaemia, a donor transplant remains central, and CAR-T is used when the disease returns or does not respond, sometimes as a bridge towards a transplant.
This is general guidance. Your own order of treatment is set by your haematologist after looking at your reports.What is being compared
What are the three options, in plain words?
Families often hear "transplant" as one thing. There are two kinds, and CAR-T is different from both.
Transplant with your own cells
Your stem cells are collected and frozen. You then have very strong chemotherapy, and the stored cells are returned to rebuild your blood and immune system. The doctors call this an autologous transplant.
Mostly used for
- Myeloma
- Lymphoma that returns and still responds to chemotherapy
Transplant from a donor
Stem cells come from a matched brother, sister, parent, child or an unrelated donor. The donor's immune cells can also attack leftover cancer. This is an allogeneic transplant, and it carries the heaviest risks of the three.
Mostly used for
- Acute leukaemias at high risk of returning
- Some lymphomas after several relapses
CAR-T cell therapy
Your own T cells, a type of white blood cell, are collected and changed in a laboratory so they can find and attack the cancer. They are grown, sent back, and given as a single drip after a short course of chemotherapy.
It is approved only for certain blood cancers, and usually only after other treatment has been tried.Not sure whether this applies to you?
Ask an oncologistSide by side
How do CAR-T and a transplant differ for the family?
Stem cell transplant
CAR-T cell therapy
Needs the cancer to respond to chemotherapy first
Can be used when chemotherapy has stopped working
A donor transplant needs a matched donor to be found
Uses your own cells, so no donor search
Very strong chemotherapy and a long hospital stay
Milder chemotherapy, but close watching for immune reactions
Main risks are infection and, with donors, graft-versus-host disease
Main risks are fever reactions, confusion and low counts
Offered at more centres across India
Offered at fewer centres, with a wait while cells are made
The decision
What does the team look at before choosing?
-
The exact type of blood cancer
The biopsy report names the type and subtype. CAR-T is approved only for some of them, so this first step rules options in or out.
-
How it responded, and when it came back
A cancer that never responded, or came back quickly, points one way. A cancer that stayed away for a long time and responds again to chemotherapy points another. Bring the dates of every treatment you have had.
-
Your fitness and other illnesses
Heart, lung and kidney function all matter. A donor transplant asks the most of the body, and some people who cannot manage it may still be able to have CAR-T.
-
Donor, access and time
Whether a matched donor exists, how fast the disease is moving, and how long the wait for cell manufacturing would be. A cancer growing quickly may not allow a long wait.
-
A tumour board discussion
At CION, the haematology team presents your case to a tumour board and then coordinates referral to a qualified transplant or CAR-T centre. Ask which option is recommended, why, and what the second choice would be.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being straight with you
Who is each option not right for?
Neither option suits everyone, and hearing that early saves families months of chasing the wrong plan.
When a transplant may not fit
A transplant with your own cells works poorly when the cancer no longer shrinks with chemotherapy. A donor transplant may not be advised for older people with serious heart, lung or kidney problems, or when no suitable donor can be found in time.
When CAR-T may not fit
CAR-T is not approved for most solid cancers, and not for every blood cancer. It may not suit someone with an active infection that is not under control, very poor organ function, or disease moving so fast that there is no time to make the cells. You also need a caregiver with you through the first weeks and a place to stay near the treating centre.
What this page cannot tell you
It cannot tell you which option will work for you, or how long its effect will last. Those answers depend on your reports, your fitness and how your disease behaves, and only your haematologist can weigh them together.
On your report
What do the words in the letters mean?
- Refractory
- The cancer did not shrink enough with treatment. This often moves CAR-T higher up the list.
- Relapsed
- The cancer went away and then came back. How soon it returned matters to the choice.
- Remission
- No sign of the cancer on tests. It does not mean the cancer can never return.
- Salvage chemotherapy
- A different chemotherapy given after relapse, usually to shrink the cancer before a transplant.
- Bridging therapy
- Treatment given to hold the cancer back while CAR-T cells are being made.
- Lines of therapy
- Each separate treatment plan you have had. Many approvals for CAR-T depend on this count.
Commonly believed
What do families get wrong about this choice?
"CAR-T is newer, so it must be better than a transplant."
Newer is not the same as right for you. For some cancers and some patterns of relapse, a transplant still has the longer track record and remains the recommended next step. The order is chosen by situation, not by how new a treatment is.
"If we try a transplant first, CAR-T is off the table."
Not usually. Many people who relapse after a transplant can still be considered for CAR-T later. The reverse can also happen, where CAR-T is used to bring the disease under control before a donor transplant.
"CAR-T is a one-day drip, so it is the easy option."
The drip is short, but the weeks around it are not. There is cell collection, a manufacturing wait, chemotherapy before the drip, and close watching afterwards for fever, confusion and infection.
"We should wait and decide after the next relapse."
Delay can close doors. Both options work better when the disease is under some control and the person is fit. Ask for a referral discussion early, even if the answer is to wait.
Questions we are asked
Common questions about CAR-T and transplant
Can I choose CAR-T instead of a transplant myself?
You can ask, and you should understand why one is recommended. The final choice depends on approvals for your type of cancer, how it has behaved and your fitness. A CAR-T centre will only accept you if you meet its criteria, so the decision is made with your haematologist, not alone.
Is CAR-T available in India?
Yes. An Indian-made CAR-T therapy has been approved for certain relapsed B-cell lymphomas and leukaemias, and some centres offer it. CION does not make or give CAR-T itself. Our haematology team reviews your case and coordinates referral to a qualified centre.
Which is more expensive, CAR-T or a transplant?
CAR-T usually costs more than a transplant with your own cells, though costs vary widely between centres and change often. Travel, stay near the centre and care for complications add to both. Ask each centre for a written estimate and check your insurance or scheme rules first.
My father is in his seventies. Is a transplant still possible?
Age alone does not decide it. Fitness, heart and lung function and other illnesses matter more. A donor transplant is harder at older ages, while a transplant with his own cells or CAR-T may still be considered. His haematologist will assess this rather than go by his age alone.
If CAR-T works, will he still need a transplant?
For lymphoma, often not. For some leukaemias, a donor transplant may still be advised after CAR-T to lower the chance of the disease returning. This depends on the type of cancer and the test results after CAR-T, so ask the treating centre what their plan is.
What if there is no matched donor in the family?
Unrelated donor registries and half-matched family donors widen the options. A donor search takes time, which is one reason the team starts looking early. If no donor is found in time, CAR-T or another treatment may be considered instead, depending on the cancer.
How long does each option keep us away from home?
Both can take several weeks. A transplant involves a long hospital stay and close follow-up. CAR-T usually means staying near the treating centre for some weeks after the drip, with a caregiver present throughout. Plan housing and leave from work before treatment starts.
Who should we speak to first?
Start with a haematologist who can review every report and treatment date together. At CION, Dr. Basudev Pokhrel and the haematology team take your case to a tumour board and help you reach the right transplant or CAR-T centre, with a clear list of questions to ask there.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Patient stories
Hear it from people we have treated
Every story is a video, in the patient's own words. Nothing here is a written testimonial.
Accreditation and empanelment
- NABH
- NABL
- ISO 9001:2015
- ArogyaSri empanelled
- CGHS accepted
- ECHS accepted
- EHS accepted
- Major cashless insurers
Paying for it
Insurance, schemes and payment
What you actually pay usually differs a great deal from the sticker figure.
AarogyasriEmpanelled. Bring the card and a referral where you have one.
CGHS / ECHS / EHSAccepted at CION centres for eligible treatment.
Cashless insuranceMost major insurers are empanelled. Pre-authorisation is handled by our desk.
Self-payItemised estimate given before treatment starts. No EMI scheme exists.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. A haematology consultation can be booked at any of these centres through one helpline, and your team will tell you where each test or treatment takes place.
Warangal
Vizag
Sources
- National Cancer Institute — CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers
- National Cancer Institute — Stem Cell Transplants in Cancer Treatment
- Leukaemia & Lymphoma Society — Chimeric Antigen Receptor (CAR) T-Cell Therapy
- NHS — Stem cell and bone marrow transplants
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
CAR-T: The GapsThe full guide to the CAR-T pathwayApheresis for CAR-T: The Cell Collection DayWhat happens when your cells are collectedThe Manufacturing Wait and What Happens MeanwhileHow the disease is held back while cells are madeRelapse After CAR-TWhat options remain if the cancer returnsLymphoma guideBackground on the cancer CAR-T is most used for
Talk to us
Not sure which route fits your reports?
Share your reports with CION's haematology team. We review the case at a tumour board and help you reach a qualified transplant or CAR-T centre.